Truist Financial
VKTX icon

Truist Financial’s Viking Therapeutics VKTX Stock Holding History

Truist Financial’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$354K Sell
9,085
-494
-5% -$16K ﹤0.01% 2438
2026
Q1 		$312K Buy
9,579
+1,396
+17% +$44.9K ﹤0.01% 2365
2025
Q4 		$288K Sell
8,183
-309
-4% -$10.9K ﹤0.01% 2361
2025
Q3 		$223K Buy
8,492
+660
+8% +$19.7K ﹤0.01% 2494
2025
Q2 		$208K Sell
7,832
-525
-6% -$13.8K ﹤0.01% 2408
2025
Q1 		$202K Sell
8,357
-483
-5% -$15.3K ﹤0.01% 2363
2024
Q4 		$356K Buy
8,840
+1,912
+28% +$109K ﹤0.01% 2061
2024
Q3 		$439K Sell
6,928
-19,121
-73% -$1.12M ﹤0.01% 1935
2024
Q2 		$1.38M Buy
26,049
+20,350
+357% +$1.33M ﹤0.01% 1455
2024
Q1 		$467K Buy
+5,699
New +$254K ﹤0.01% 2004

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Truist Financial's VKTX Position: Q2 2026 in Review

Truist Financial reduced its Viking Therapeutics (VKTX) stake by 5.2% in Q2 2026, selling an estimated $16K and leaving 9,085 shares worth $354K. The position accounts for ﹤0.01% of the portfolio, ranked #2438.

Truist Financial first reported a position in VKTX in Q1 2024 and has held it in 10 quarters since. The position peaked at $1.38M in Q2 2024. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Truist Financial held 9,085 shares of Viking Therapeutics worth $354K as of Q2 2026.
  • Truist Financial sold 494 Viking Therapeutics shares in Q2 2026, an estimated $16K.
  • Viking Therapeutics made up ﹤0.01% of Truist Financial's portfolio in Q2 2026, its #2438 holding.
  • Truist Financial first reported a position in Viking Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • Truist Financial's Viking Therapeutics position peaked at $1.38M in Q2 2024.
  • 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Truist Financial's 13F filing for Q2 2026, filed 28 Jul 2026.